Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 2, 2012, Pages 178-184

  Tannheimer, Stacey L ^a   Sorensen, Eric A ^a   Haran, Aaron C ^a   Mansfield, Christopher N ^a   Wright, Clifford D ^a   Salmon, Michael ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

CAMP; Dexamethasone; PBMC; PDE4; Roflumilast; Salmeterol

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; FORMOTEROL; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; ROFLUMILAST; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; CYCLOPROPANES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; PHOSPHODIESTERASE 4 INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858276693     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.01.003     Document Type: Article

References (42)

1. Hatzelmann A., Morcillo E.J., Lungarell G., Adnot S., Sanjar S., Beume R., et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23:235-256.
2. Gross N.J., Giembycz M.A., Rennard S.I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010, 7:141-153.
3. Cazzola M. The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. Ther Adv Respir Dis 2010, 4:195-198.
4. Johnson M. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002, 110:S282-S290.
5. Johnson M., Rennard S.I. Alternative mechanisms for long-acting beta2-adrenergic agonists in COPD. Chest 2001, 120:258-270.
6. Maneechotesuwan K., Essilfie-Quaye S., Meah S., Kelly C., Kharitonov S.A., Adcock I.M., et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005, 128:1936-1942.
7. Jeffery P.K., Venge P., Gizycki M.J., Egerod I., Dahl R., Faurschou P. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002, 20:1378-1385.
8. Chung K.F., Caramori G., Adcock I.M. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Invest 2009, 65:853-871.
9. Remington T.L., Digiovine B. Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 2005, 11:74-78.
10. Johannessen M., Delghandi M.P., Moens U. What turns CREB on?. Cell Signal 2004, 16:1211-1227.
11. Giembycz M.A., Newton R. Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Eur Respir J 2006, 27:1286-1306.
12. Salpeter S., Ormiston T., Salpeter E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004, 140:802-813.
13. Lundblad L.K., Rinaldi L.M., Poynter M.E., Riesenfeld E.P., Wu M., Aimi S., et al. Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. Respir Res 2011, 12:12-27.
14. Wraight J.M., Smith A.D., Cowan J.O., Flannery E.M., Herbison G.P., Taylor D.R. Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. Respirology 2004, 9:215-221.
15. Nino G., Hu A., Grunstein J.S., Grunstein M.M. Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2009, 297:L746-L757.
16. Seybold J., Newton R., Wright L., Finney P.A., Suttorp N., Barnes P.J., et al. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization. J Biol Chem 1998, 273:20575-20588.
17. Conti M., Richter W., Mehats C., Livera G., Park J.Y., Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003, 278:5493-5496.
18. Diamant Z., Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther 2011, 24:353-360.
19. Seldon P.M., Barnes P.J., Meja K., Giembycz M.A. Suppression of lipopolysaccharide-induced tumor necrosis factor-a generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995, 48:747-757.
20. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-279.
21. Seldon P.M., Meja K.K., Giembycz M.A. Rolipram, salbutamol and prostaglandin E2 suppress TNFalpha release from human monocytes by activating Type II cAMP-dependent protein kinase. Pulm Pharmacol Ther 2005, 18:277-284.
22. Tralau-Stewart C.J., Williamson R.A., Nials A.T., Gascoigne M., Dawson J., Hart G.J., et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther 2011, 337:145-154.
23. Farmer P., Pugin J. Beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkB/NF-kB pathway. Am J Physiol Lung Cell Mol Physiol 2000, 279:L675-L682.
24. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990, 265:5267-5272.
25. Lemoine H., Ehle B., Kaumann A.J. Direct labelling of beta 2-adrenoceptors. Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551. Naunyn Schmiedebers Arch Pharmacol 1985, 331:40-51.
26. Bilski A.J., Halliday S.E., Fitzgeralk J.D., Wale J.L. The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol 1980, 5:430-437.
27. Fabbri L.M., Calverley P.M.A., Izquierdo-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet 2009, 374:695-703.
28. Summerhill S., Stroud T., Nagendra R., Perros-Huguet C., Trevethick M. A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. J Pharmacol Toxicol Methods 2008, 58:189-197.
29. Donnelly L.E., Tudhope S.J., Fenwick P.S., Barnes P.J. Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur Respir J 2010, 36:178-186.
30. Bruss M.D., Richter W., Horner K., Jin C., Conti M. Critical role of PDE4D in beta2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts. J Biol Chem 2008, 283:22430-22442.
31. Scott M.G., Swan C., Jobson T.M., Rees S., Hall I.P. Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells. Br J Pharmacol 1999, 128:721-729.
32. Bryn T., Mahic M., Enserink J.M., Schwede F., Aandahl E.M., Tasken K. The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 2006, 176:7361-7370.
33. Stafford J.B., Marnett L.J. Prostaglandin E2 inhibits tumor necrosis factor-alpha RNA through PKA type I. Biochem Biophys Res Commun 2008, 366:104-109.
34. Aronoff D.M., Canetti C., Serezani C.H., Luo M., Peters-Golden M. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol 2005, 174:595-599.
35. Kreckler L.M., Gizewski E., Wan T.C., Auchampach J.A. Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. J Pharmacol Exp Ther 2009, 331:1051-1061.
36. Freeman C.M., Curtis J.L., Chensue S.W. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Path 2007, 171:767-776.
37. Taylor D.R. Risk assessment in asthma and COPD: a potential role for biomarkers?. Thorax 2009, 64:261-264.
38. Prabhakar U., Lipshutz D., Bartus J.O., Slivjak M.J., Smith E.F., Lee J.C., et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994, 16:805-816.
39. Marjanovic M., Bosnar M., Michielin F., Wille D.R., Anic-Millic T., Culic O., et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 2011, 63:389-397.
40. Ammit A.J., Hoffman R.K., Amrani Y., Lazaar A.L., Hay D.W., Torphy T.J., et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate. Am J Respir Cell Mol Biol 2000, 23:794-802.
41. Meyers J.A., Taverna J., Chaves J., Makkinje A., Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res 2007, 13:4920-4927.
42. Tiwari S., Dong H., Kim E.J., Weintraub L., Epstein P.M., Lerner A. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 2005, 69:473-483.